Fenofibrate And Microvascular Events in Type 1 Diabetes (FAME 1) Trial [ 2014 - 2018 ]

Also known as: FAME 1 - Eye

Research Grant

[Cite as]

Researchers: Prof Alicia Jenkins (Principal investigator) ,  Prof James Best Prof Kim Donaghue Prof David O'Neal

Brief description Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.

Funding Amount $AUD 2,883,529.09

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]